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Abstract
Background: Preterm birth is the leading cause of mortality and disability in newborn and infants. Having a short
cervix increases the risk of preterm birth, which can be accessed by a transvaginal ultrasound scan during the
second trimester. In women with a short cervix, vaginal progesterone and pessary can both reduce this risk, which
progesterone more established than cervical pessary. The aim of this study is to compare the use of vaginal
progesterone alone versus the association of progesterone plus pessary to prevent preterm birth in women with a
short cervix.
Methods: This is a pragmatic open-label randomized controlled trial that will take place in 17 health facilities in
Brazil. Pregnant women will be screened for a short cervix with a transvaginal ultrasound between 18 0/7 until 22 6/7
weeks of gestational age. Women with a cervical length below or equal to 30 mm will be randomized to the
combination of progesterone (200 mg) and pessary or progesterone (200 mg) alone until 36 + 0 weeks.
The primary outcome will be a composite of neonatal adverse events, to be collected at 10 weeks after birth. The
analysis will be by intention to treat. The sample size is 936 women, and a prespecified subgroup analysis is
planned for cervical length (= < or > 25 mm).
Categorical variables will be expressed as a percentage and continuous variables as mean with standard deviation.
Time to delivery will be assessed with Kaplan-Meier analysis and Cox proportional hazard analysis.
Discussion: In clinical practice, the combination of progesterone and pessary is common however, few studies
have studied this association. The combination of treatment might act in both the biochemical and mechanical
routes related to the onset of preterm birth.
Trial registration: Brazilian Clinical Trial Registry (ReBec) RBR-3t8prz, UTN: U1111–1164-2636, 2014/11/18.
Keywords: Pessaries, Progesterone, Cervical length measurement, Randomized controlled trial
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: rodolfop@unicamp.br
1Department of Obstetrics and Gynecology, School of Medical Sciences,
University of Campinas – UNICAMP, Rua Alexander Fleming, 101 Cidade
Universitária Zeferino Vaz, Campinas 13087-460, Brasil
Full list of author information is available at the end of the article
Pacagnella et al. BMC Pregnancy and Childbirth          (2019) 19:442 
https://doi.org/10.1186/s12884-019-2513-2
Background
Preterm birth (PTB), defined as birth before 37 weeks of
gestation, is in quantity and in severity one of the most
important issue in obstetric care in the world. Globally,
around 15 million preterm births are born every year
[1]. In 2014 the United States it was 9.5% in 2014, while
in Brazil, according to the national registry of living births
system (SINASC), PTB rate was 9.9% in 2012 [2, 3]. The
recent WHO report Born too Soon estimates the number
of preterm births in Brazil to be 279,300 (9.1% of live
births) [1]. Its prevalence has increased by 30% in the last
30 years and Brazil features among the top-10 countries
with the highest numbers of preterm births [4]. Some data
suggest that the real prevalence of preterm birth in Brazil
approaches 10% [5].
Being born premature increases the risk of death by
other causes as infections and is associated with lifelong
sequelae such as cerebral palsy, visual deficiency and
lower school performance [6]. Prematurity is the major
cause of neonatal deaths worldwide and the second most
important cause in children under 5 years, after pneu-
monia. Only in 2010 prematurity was responsible for
35% of 3.1 million neonatal deaths [4].
PTB is a multifactorial condition. The increase in ma-
ternal age at conception, multiple pregnancies, and ma-
ternal and neonatal related conditions are some of these
factors that lead to therapeutic and spontaneous preterm
labor. Women with previous PTB, preterm premature
rupture of membranes (PPROM), and preterm labor also
have a higher risk of PTB [7]. Even knowing some of the
causes, almost 50% of the spontaneous PTB have no
identifiable cause [7] and a significant reduction of PTB
rates has not been accomplished so far.
One raising strategy to reduce PTB is to pay attention
to physiological modifications that precede preterm
labor in the uterine cervix: the cervical length shortening
[8]. There is an inverse relationship between mid-
trimester cervical length and the risk of preterm birth
that varies as a function of the gestational age at the
time the cervical shortening is diagnosed [6].
The process of cervical effacement begins some weeks
before preterm labor and cervical shortening diagnosed
between the 16th and 24th weeks is an important etio-
logical factor for preterm delivery [9]. This has been dem-
onstrated in populations with different risk profiles,
varying from asymptomatic women with low-risk single-
ton pregnancies to women with high-risk pregnancies due
to previous preterm birth or a twin pregnancy [10–12].
The best way to identify cervical shortening is by using
transvaginal ultrasound examination performed between
the 16th and 24th weeks of gestation. Although the cut-
off limit for the cervical length that represents a risk for
preterm delivery is subject to debate, the relative risk of
preterm delivery among women with cervical length
below the 25th percentile (30 mm) was shown to be at
almost 4 times higher than for those above 40mm [13].
Today, strategies to predict PTB include sonographic
measurement of the cervical length. The shortening of
cervical length is a common pathway leading to preterm
labor. The shorter the cervix, the greater the risk of
PTB, therefore, there may be an important role to screen
for risk of preterm birth using cervical shortening [8].
Cervical length measure is best accessed by transvaginal
ultrasound scan between 16 and 24 weeks and can be
performed along with the routine second-trimester
ultrasound [14].
When a short cervix is diagnosed during the second
trimester, maternal use of progesterone reduces the rate
of PTB with 30–45% [15–17]. A meta-analysis [15] indi-
cated progestational agents generated lower rates of pre-
term delivery in women with a short cervix (26.2% vs
35.9%; OR 0.45, 95% CI 0.25–0.80). Relative to women
allocated to receive placebo, those who received proges-
tational agents also had lower rates of perinatal mortality
(14.8% versus 17.1%; OR 0.69, 95% CI 0.38–1.3).
Progesterone can be used as either intramuscular (17
alpha-hydroxyprogesterone caproate 250 mg), subcuta-
neous (progesterone 25mg), vaginal gel (progesterone
80mg) or vaginal capsules (micronized progesterone
200 mg) but there is some evidence that vaginal proges-
terone is superior to other presentations to prevent PTB
[18], and seems to be safe for the mother and the fetus
[19]. Twin pregnancies have also a higher risk of PTB,
but progesterone is not effective in unselected women
with a twin pregnancy. However, the use of progesterone
in patients with twin gestation and short cervix seems
promising [20].
Another promising intervention to prevent preterm
delivery is the use of a cervical pessary. The pessary
seems to exert its effect through mechanically changing
the cervico-uterine angle, reducing the compression of
the cervix and protecting the cervical mucus [21]. Stud-
ies in both twins and singletons have indicated that the
cervical pessary may be an effective intervention in the
prevention of spontaneous preterm birth and the harm
resulting from it.
Although some studies have failed to demonstrate
benefits of the pessary for PTB both in singletons and
twins [22–26], others [27–30] have shown a significant
reduction in PTB rate in women with short cervix using
a pessary. The PECEP trial was the first well-conducted
randomized control trial [27] showing that in women
with a short cervical length, the use of a cervical pessary
reduces the preterm birth rate.
In summary, treatment with both pessary and proges-
terone might be helpful in reducing the rate of preterm
birth. Both interventions have shown to be safe and reli-
able, as no maternal or fetal severe outcomes due to the
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use of these interventions have been demonstrated.
However, the combination of progesterone and pessary
for the prevention of PTB has not been tested yet. A
combination could guide both pathways: the biochemical
(progesterone) and mechanical (pessary), making the
combined treatment more effective than a single treat-
ment, acting in a broader set of women at risk for PTB
[31, 32].
The aim of this study is to compare the effectiveness
of the use of progesterone alone versus the combination
of progesterone plus pessary to prevent PTB in women
with short cervical length.
Methods
This is a pragmatic, multicentre, open-label randomized
controlled trial (RCT), testing the effectiveness of pes-
sary plus progesterone versus progesterone alone in re-
ducing preterm birth and a composite of neonatal
adverse events.
Governance
The coordinating center of the study is the Women’s
Hospital at the University of Campinas in Brazil. There
are 17 reference obstetric units in different geographic
regions of Brazil as participating centers, including aca-
demic and general maternity hospitals and other health
facilities such as ultrasound clinics and prenatal care
units. The study participating centers are all members of
the Brazilian Network for Studies in Reproductive and
Perinatal Health. Each center has a local investigator,
who may also select research assistant medical doctors
to proceed with the intervention.
The study will be overseen by a Steering Committee
(SC-P5) and a Data Safety and Monitoring Board
(DSMB-P5). The SC-P5 is composed of the principal in-
vestigators, researchers of recognized national and inter-
national competence, a representative of an NGO dealing
with preterm birth patients and members of the funding
agencies (Bill & Melinda Gates Foundation, National
Council for Scientific and Technological Development
(CNPq) Ministry of Health) to evaluate the progress of the
study and suggest changes when necessary.
The DSMB-P5 is composed of researchers of recog-
nized national and international competence without
any participation in the study group with the support of
a statistician. This committee has complete access to the
database and will meet at prespecified moments.
The Brazilian National Review Board (CONEP) ap-
proved the study under the number 1.055.555. Each
local Institutional Review Boards also approved the
study protocol. Protocol modifications will be reported
to each relevant part including national and local institu-
tional review boards and will be available to trial partici-
pants through the project website, to the investigators by
an internal bulletin, to the registries and journals by
publications, and to regulators by the review board re-
port. No funding agency had any influence on the design
and decision regarding data collections, managements,
analysis and writing.
Trial organization
A Standard Operation Procedure with video classes was
developed, provided to all centers and available online,
with information on how to collect and store data, how
to proceed with randomization, follow-up, and out-
comes. The number of subjects will be monitored
weekly by the project coordinators, monitoring visits to
the other participating centers twice a year. The reports
from this monitoring process will be available to the
monitoring committees and to the centers themselves to
document the need for improvement.
The research assistant will collect informed consent
before submitting the participant to the ultrasound scan,
and in case of the short cervix, another consent will be
applied before the randomization. Data will be kept con-
fidential during the study. The name and the personal
information will be stored in a database different from
the main results and will be available only to each re-
spective local coordinator during the follow-up. After
the end of the study personal data will be split from the
clinical results and will be available only to the principal
investigator (PI).
The final dataset will be available to the PI and collabor-
ating researchers. If necessary, participants will receive an-
cillary and post-trial care, as compensation if there is any
harm secondary to the participation on the trial. The PIs
do not have any competing interests for the trial. Trial re-
sults will be published as scientific articles, and authorship
eligibility will be considered according to the International
Committee of Medical Journal Editors recommendations.
Participating centers are listed in Fig. 1.
Inclusion and exclusion criteria
We will study women with a singleton or twin preg-
nancy. Pregnant women, no maternal age restriction, at
a gestational age between 18 0/7 and 22 6/7 weeks will be
offered cervical length measurement by ultrasound (US).
Women with a cervical length below or equal to 30 mm
(but more than 5mm) are eligible for the trial.
Exclusion criteria are painful contractions, vaginal
bleeding, cerclage during current pregnancy before the
screening, PPROM, severe liver disease, cholestasis dur-
ing this pregnancy, previous or current thromboembol-
ism, placenta previa, cervical dilation greater than 1 cm,
monoamniotic twin pregnancy, higher order twin preg-
nancy (triplets or higher), major fetal malformation of at
least one fetus and stillbirth.
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Ultrasound training
All participating members of the research team are
trained to perform the cervical measurement by ultra-
sound and to manage the pessary. All sonographers are
trained in cervical measurement according to The Fetal
Medicine Foundation training program [33] and are en-
couraged to follow its certification program. Addition-
ally, an online training program (using Moodle platform)
was created to certificate all sonographers involved in
the P5 study in standardizing cervical measurements,
and at this Moodle platform, all participants of the re-
search had signed the disclosure of contractual agree-
ments that limit such access for investigations. The
ultrasound examination will be performed using a GE
Logic C5® equipment.
Recruitment and enrolments
A research assistant will invite women attending the
ultrasound department of each institution or outpatient
clinics involved in the study to participate in the screen-
ing strategy and, after being informed about the study,
to sign a written Informed Consent Form. A transvaginal
ultrasound scan to measure cervical length as described
above will be performed.
Women with a short cervix and without any exclusion
criteria will then be invited to participate in the
randomized clinical trial. After being informed about the
study verbally and with a written patient information
leaflet, women will be asked to sign an Informed Con-
sent Form. Only after written informed consent, the
local investigator will randomly assign patients. In case
of an eligible participant under 18 years old, a consent
form will be signed for both the underaged participant
and his/her legal guardian/parent before been admitted
into the study.
Randomization
After written informed consent, women will be random-
ized into two groups: the use of pessary plus progester-
one or the use of progesterone alone. Randomization
will be stratified by center, number of fetuses (one or
two) and cervical length (< 25mm or 25-30 mm) using a
1:1 ratio and variable block sizes. Randomization is per-
formed electronically in an online database added as a
specific form in the online data collection system, using
computer-generated random numbers. The system can
be accessed 24/7 and a phone number is available to
help the inclusion and randomization process. Each local
coordinator will be responsible for the randomization
process including enrollment and assignment of women
to interventions.
Fig. 1 Participating centers and location
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Interventions
Since the use of the pessary cannot be blinded, this is an
open-label RCT. The pessary used is an Arabin type pes-
sary registered at the national health surveillance agency
of Brazil (Pessário AM® by Ingamed) with the dimensions:
inner circle 30mm; outer circle 70mm; height 25mm.
A physician trained specifically for pessary placement
will insert the pessary up to 72 h from the randomization.
An ultrasound scan to re-assess cervical length and pes-
sary placement will be performed after its insertion.
We will use 200 mg micronized progesterone capsules
that will be self-administered digitally inserted into the
vagina every night. Commercial Progesterone (Utroges-
tam®) pills will be purchased from Besins Healthcare
Pharmaceutics. Both interventions will be maintained
until 36 weeks gestation unless antenatal care providers
consider the need to withdrawal earlier.
The intervention will be discontinued before 36 weeks
only if the assistant medical doctor judges it is necessary
due to clinical conditions, or in case of woman request.
Every enrolled woman will receive access to a P5 phone
number for her to call in case of doubts or need to re-
port side events. A research assistant will be full time
available for solving such questions.
Women with threatened preterm labor will be treated
with tocolysis, corticosteroids and magnesium sulfate ac-
cording to local protocols.
Follow-up
Prenatal care will continue in each reference facility con-
sidering local protocols. In each visit, the participant will
be asked about the use of progesterone and pessary,
symptoms, adverse events, and admission to hospital.
She will receive enough progesterone until the next ap-
pointment when more capsules will be delivered. One
research assistant per center will follow up all enrolled
women avoiding double data collection. Adherence
monitoring will be checked in all visits with the woman
returning her drug table.
All enrolled women will be followed-up until 10 weeks
after birth. To avoid a loss to follow-up, participants will be
contacted by telephone if they miss an appointment. Com-
pliance will be measured by the number of progesterone
pills returned by the subject at each antenatal care visits.
Outcomes
Our primary outcome is a composite of neonatal adverse
events: periventricular leukomalacia (focal periventricu-
lar necrotic and diffuse gliosis in the surrounding cere-
bral white matter that may have cystic lesions secondary
to necrotic foci in the white matter) [34], severe respira-
tory distress syndrome (grunting, retractions, or other
typical distress symptoms in a premature infant immedi-
ately after birth with a chest radiography showing
homogenous opaque infiltrates and air bronchograms)
[35], bronchopulmonary dysplasia (infant requiring
treatment with > 21% oxygen for at least 28 days) [36],
periventricular hemorrhage grade II (hemorrhage is
present in a nondistended lateral ventricle) or higher
[37], necrotizing enterocolitis (spectrum of intestinal
conditions including feeding intolerance, mild abdominal
distention, spontaneous intestinal perforations and intes-
tinal necrosis) [38], proven sepsis before discharge (gen-
eralized bacterial infection occurring within the neonatal
period up to 4 weeks beyond the expected date of deliv-
ery accompanied by a positive blood culture) [39], still-
birth, or neonatal death.
Secondary outcomes will be gestational age at birth,
birth weight, adequacy of birth weight for gestational
age, first and fifth minute Apgar score, neonatal gesta-
tional age, overall, spontaneous and medical induced
PTB rate before 28, 32, 34 and 37 weeks of gestation,
PPROM rate, neonatal intensive care unit (NICU) ad-
mission and length of stay, maternal morbidity and mor-
tality, maternal length of stay in hospital, maternal ICU
admission, cost-benefit analysis of the screening pro-
gram, treatment cost, maternal inpatient treatment costs,
neonatal inpatient treatment costs and pessary use un-
wanted effects [40, 41].
Information on readmissions of mother and/or new-
born and primary and secondary outcome will be col-
lected during hospitalization for birth and at 10 weeks
after due date, by telephone contact and patient’s regis-
tries review.
Sample size
Considering the reduction in the risk of preterm delivery
by the pessary described by the PECEP clinical trial [27],
and considering our own outcomes in women with a
short cervix, we anticipate a composite poor neonatal
outcome rate of 22%. We consider a reduction of 10% as
clinically relevant. The reduction from 22 to 12% in the
composite poor neonatal outcomes (2-sided alpha 0.05,
80% power) can be detected if 438 women are random-
ized (219 per group). To assure a subgroup analysis for
cervical length less than or equal to 25 mm, considering
a reduction of 50% in adverse neonatal outcomes (17.3
to 8.65% [15]), it will be necessary to increase a sample
to 468 women (234 per subgroup). Thus, the final sam-
ple should be composed of 936 women (468 in each
group, 234 per subgroup).
Data collection
The data will be collected using an online database,
which is a new generation of application systems that
allow the collection and cleaning of clinical trial data
using the Internet. This technology was developed
Pacagnella et al. BMC Pregnancy and Childbirth          (2019) 19:442 Page 5 of 9
specifically for the study using an existing certified platform
for medical offices management. The online database has
distinct permission levels and is encrypted and protected by
a personal security password. Data will be stored in cloud
network and a backup is being performed every day.
The forms and the randomization process are inserted
in the platform and access is given to each facility coordin-
ator and research assistant for local data management.
Each local coordinator is responsible for data entry. Data
will be collected in printed forms or directly in the online
form, available in the same online database where the
randomization takes place, by a trained research assistant.
The local coordinator will verify these data in the printed
and online system, to assure the information is correct.
Data analysis
Data analysis will be performed according to the
intention-to-treat principle. A statistical analysis plan
will be finalized prior to the data lock.
Categorical variables will be expressed by the relative
frequency on the corresponding allocation arm. For con-
tinuous variables minimum, first quartile, median, third
quartile, maximum, mean, and standard deviation will be
presented. Missing values will be reported for all variables.
The primary outcome is a binomial random variable. For
this outcome, we will estimate a risk ratio (RR) with 95% CI.
We will also calculate rates in the two groups as well as the
number needed to treat (NNT). The comparisons of treat-
ments will be performed with a generalized linear model
[42], with the log link function. The model will include
treatment as main effect and a full factorial of study center,
type of pregnancy (twin or singleton) and cervix length (two
categories). The main analysis will be performed using stra-
tums according the randomization process. All factors are
fixed. The factors study center, type of pregnancy and cervix
length figure as randomization block terms.
An additional model including cervical length as con-
tinuous covariate will also be analyzed. The model better
adjusted will be used as final model. The Akaike Infor-
mation Criterion (AIc) e Bayesian Information Criterion
(BIC) will be used to decide among models. To evaluate
the potential efficacy of the pessary, a per-protocol ana-
lysis will also be performed.
Secondary outcomes will be analyzed using generalized
linear models with treatment as main effect and a full
factorial of study center, type of pregnancy (twin or
singleton) and cervix length (two categories). All factors
are fixed. An appropriated link function will be chosen
to each response variable.
An additional model including cervical length as con-
tinuous covariate will also be analyzed. The model better
adjusted will be used as final model. The Akaike Infor-
mation Criterion (AIc) e Bayesian Information Criterion
(BIC) will be used to decide among models.
Survival analysis to assess time to delivery will also be
performed using Kaplan Meier and Cox Proportional
Hazard Model. Differences in treatments among sub-
groups will be assessed including in the statistical
models already described above a subgroup variable and
a interaction term subgroup-treatment. These are the
subgroups to be analyzed:
– Singleton and twin pregnancies
– Cervical length (≤25 mm / > 25 mm)
– Nulliparous/ multiparous
– Previous spontaneous preterm birth
– Obstetric US abnormalities or sludge at
randomization
– Ethnicity (white / non-white)
The DSMB-P5 will meet at predetermined intervals
(after half of the randomized cases and after 2/3 of the
randomized cases) to analyze the results regarding the
possible adverse effects of the interventions or regarding
the achievement of statistical significance for the main
outcome. Other interim analyses will be calculated ac-
cording to DSMB-P5 request. The committee will have
the power to recommend completion of the study or an
early interruption based on the evaluation of the interim
results and on some pre-specified stopping rules.
Timetable
The study started woman enrolment in July 2015. Chrono-
gram considers finishing enrolment in April 2019. Final re-
ports and publication are expected by December 2019.
Registration and version
The study protocol was registered in the Brazilian Clin-
ical Trial Registry (ReBec) on November 18th, 2014 and
the register number is RBR-3t8prz UTN: U1111–1164-
2636. This is the version 7 of the protocol. This manu-
script adhered to SPIRIT guidelines/methodology.
Discussion
Preterm birth is still an important condition in obstetrics;
however, a significant reduction of PTB rates has not been
accomplished so far. It is a complex syndrome involving in-
flammatory agents and epigenetic factors and few strategies
have being proven to reduce the risk of preterm birth, being
the use of progesterone the most effective intervention for
preventing PTB in singleton pregnancy [43, 44].. Cervical
pessary have also shown a role in the reduction of spontan-
eous preterm birth at < 37weeks, without negatively affect-
ing maternal or neonatal outcomes [45].
Although in clinical practice the combination of pro-
gesterone and pessary is common, few studies have stud-
ied the association of treatments in the reduction of
preterm birth [46]. A previous cohort study showed that
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the association of cervical pessary and vaginal progester-
one did not reduce the risk of PTB as compared to the
use of the pessary alone [32]. Another study suggested
that the combination cervical pessary plus daily vaginal
progesterone does not reduce the rate of preterm birth
compared with vaginal progesterone alone [47]. However
these studies are small and susceptible to bias, therefore,
more studies are needed [46].
Treatment with both pessary and progesterone might
work in synergy acting in both the biochemical (progester-
one) and mechanical (pessary) routes related to the onset
of preterm birth [31, 32]. We believe that the present trial
may offer high-level evidence for the prevention of PTB.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12884-019-2513-2.
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